AIM | tickerfilter.com

Fundamental analysis

20%

Profitability 0%

Dept financing 25%

Liquidity 14%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-21.57%

1 Month

-28.65%

3 Months

-30.12%

6 Months

-30.12%

1 Year

-30.12%

2 Year

-30.12%

Key data

Stock price

$0.09

P/E Ratio

0.00

DAY RANGE

$0.06 - $0.12

EPS

-$0.10

52 WEEK RANGE

$0.06 - $0.16

52 WEEK CHANGE

-$30.12

MARKET CAP

12.614 M

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-15-2025

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$656,419

AVERAGE 30 VOLUME

$494,423

Company detail

CEO: Thomas K. Equels
Region: US
Website: aimimmuno.com
Employees: 20
IPO year: 1996

Issue type:
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

AIM ImmunoTech Inc. focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS) It is also developing Ampligen for the. treatment of renal cell carcinoma, malignant melanoma,. non-small cell lung, ovarian, breast,. breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis

AIM - AIM ImmunoTech Inc.